A Phase II intra‐patient dose‐escalation trial of weight‐based darbepoetin alfa with or without granulocyte‐colony stimulating factor in myelodysplastic syndromes
暂无分享,去创建一个
P. Lavori | P. Greenberg | J. Gotlib | R. Stein | S. Shahnia | S. Quesada
[1] P. Nguyen,et al. Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.
[2] M. Cazzola,et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] H. Dombret,et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. , 2008, Blood.
[4] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[5] L. Mannone,et al. High‐dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study , 2006, British journal of haematology.
[6] S. Amadori,et al. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] I. Dybedal,et al. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. , 2005, Blood.
[8] F. Lanza,et al. Darbepoetin alpha for the treatment of anaemia in low‐intermediate risk myelodysplastic syndromes , 2005, British journal of haematology.
[9] E. Berg,et al. World Health Organization Classification of Tumours , 2002 .
[10] B. Cheson,et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.
[11] V. Diehl,et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony‐stimulating factor and erythropoietin , 2000, British journal of haematology.
[12] J. Juncà,et al. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group. , 1999, Haematologica.
[13] P. Greenberg,et al. Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model , 1997, British journal of haematology.
[14] P. Greenberg. Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes. , 1996, Seminars in hematology.
[15] E. Hellström-Lindberg. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta‐analysis of 205 patients from 17 studies , 1995, British journal of haematology.
[16] D. Prados,et al. [Human recombinant erythropoietin in the treatment of myelodysplastic syndromes anemia. Meta-analytic study]. , 1994, Sangre.
[17] P. Greenberg,et al. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. , 1993, Blood.
[18] M. Arning,et al. Serum erythropoietin concentrations in patients with myelodysplastic syndromes. , 1991, Leukemia research.
[19] B. Brenner,et al. In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes. , 1990, Leukemia.
[20] D. Galton. The myelodysplastic syndromes. , 1987, Clinical and laboratory haematology.